From a UK perspective, BUD/F delivered via an MDI + VHC offers an economic benefit for the treatment of patients with mild asthma. Further analysis is required to determine if there would be any quality-adjusted life-year (QALY) effects based on the chosen intervention.
Cost Effectiveness Comparison of a Dry Powder Inhaler to a Metered Dose Inhaler plus Valved Holding Chamber based on an In-Vitro Drug Delivery Model
